Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: Correlation with phenotypic characteristics and outcome

Blood

Volumn 97, Issue 1, 2001, Pages 256-263

  Fayad, Luis ^a   Keating, Michael J ^a   Reuben, James M ^a   O'Brien, Susan ^a   Lee, Bang Ning ^a   Lerner, Susan ^a   Kurzrock, Razelle ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 6; LACTATE DEHYDROGENASE;

ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL; TREATMENT OUTCOME; VOLUNTEER;

EID: 0035160749     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.1.256     Document Type: Article

References (59)

1. Interleukin-6: An overview
2. The biology of Interleukin-6
3. Interleukin-6 and the acute phase response
4. A possible autocrine role for interleukin-6 in two lymphoma cell lines
5. Constitutive production of the IL-5 and IL-6 by the lymphoma cell line OCI-Ly 17 derived from a patient with malignant lymphoma and hypereosinophilia
6. Cytokine (Interleukin-1 alpha, Interleukin-1 beta, tumor necrosis factor alpha, and Interleukin-6)-possessing cells in lymph nodes of malignant lymphoma
7. Functional heterogeneity and pathogenic significance of Interleukin-6 in B-cell lymphomas
8. Interleukin-6 gene expression in normal and neoplastic B cells
9. Immunohistochemical in situ demonstration of cytokines in Hodgkin's and non-Hodgkin's lymphoma
10. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe immunodeficiency virus infection receiving antiretroviral therapy
11. Expression of an exogenous interleukin-6 gene in human Epstein-Barr virus B cells confers growth advantage and tumorigenicity
12. Long-term consequences of interleukin-6 overexpression in transgenic mice
13. Interleukin-6 production in post-transplant lymphoproliterative disease
14. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma
15. Prognostic value of serum interleukin-6 in diffuse large cell lymphoma
16. Increased levels of circulating interleukin-6 in patients with Hodgkin's disease
17. Serum interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms
18. Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgkin's disease
19. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma
20. Serum level of interleukin 6 as a prognosis factor in metastatic renal carcinoma
21. Interleukin-6: A candidate mediator of human prostate cancer morbidity
22. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer
23. Inteleukin-6 is a prognostic factor in multiple myeloma
24. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: Correlation with disease activity and other prognostic parameters
25. Two types of mouse helper T cell. IV. Th2 clones secrete a factor that inhibits cytokine production by the Th1 clones
26. Human B-cell Interleukin-10: B-cell derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin 10
27. Production of cytokines by mouse B cells: Lymphomas and normal B-cells produce interleukin 10
28. (B-1) cells are the main source of B-cell derived IL-10
29. Interleukin-10 (IL-10) a new B-cell stimulatory factor: Unresponsiveness of X-chromosome linked immunodeficiency B cells
30. IL-10 is a potent growth factor for activated human B lymphocytes
31. Interleukin-10: A novel stimulator factor for mast cells and their progenitors
32. Serum interleukin-10 in non-Hodgkin's lymphoma: A prognostic factor
33. Interleukin-10 in non-Hodgkin's lymphoma
34. Serum levels of interlukin-10 in patients with diffuse large ceil lymphoma: Lack of correlation with prognosis
35. Presence of Epstein-Barr virus viral interleukin-10 in the serum of patients with human immunodeficiency virus-related diffuse large-cell non-Hodgkin's lymphomas
36. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure free survival
37. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
38. The international standard for interleukin-6: Evaluation in an international collaborative study
39. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-α
40. Non-parametric estimation from incomplete observations
41. Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas
42. Interleukin-6 levels in the plasma of patients with lymphoma
43. Antiphospholipid antibodies: Prevalence, clinical significance and correlation to cytokine levels in acute myelogenous leukemia and non-Hodgkin's lymphoma
44. Production of interleukin-6 in high-grade B lymphomas
45. Interleukin-6 production in high-grade B lymphomas: Correlation with the presence of malignant immunoblast in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients
46. Proliferation of the BCL1 B cell lymphoma induced by IL-4 IL-5 is dependent on IL-6 and GM-CSF
47. Interleukin-6 (B-cell stimulatory factor-2)-dependent growth of a Lennert's lymphoma-derived T-cell line (KT-3)
48. 2 interferon involved
49. In vitro regulation of carcinoembryonic antigen (CEA) and class I HLA expression in human colon xenografts by interleukin-6 (IL-6) and the possible role of intrinsic interferon-induction
50. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors
51. Peripheral blood normal polyclonal B cells from patients with B-CLL produce B-cell stimulatory cytokines
52. Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta
53. Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukemia
54. + B cells
55. The role of niterleukin-10 (IL-10) in chronic B-lymphocytic leukemia: IL-10 prevents leukemic cells from apoplotic cell death
56. Interleukin-10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells
57. The serum β-2 microglobulin (β2M) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL)